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Distribution of MHC class H alleles in primary systemic vasculitis.
Previous studies have shown a number of different associations between
major histocompatibility complex (MHC) alleles and primary systemic
vasculitis. Disease heterogeneity and the lack of specificity of certain MHC
typing techniques may have contributed to the lack of consistency in those
studies. We therefore studied a relatively homogeneous group of 94
patients with Wegener's granulomatosis, microscopic polyangiitis, or
renal-limited vasculitis using molecular techniques that allow more precise
assignment of MHC genotype. DNA was prepared from peripheral blood
and DRB1 genotype determined by Taq restriction fragment length
polymorphism. DQB1 and DPB1 genotype were assigned by polymerase
chain reaction amplification followed by probing with allele-specific
oligonucleotides. Specificity of associated anti-neutrophil cytoplasm anti-
bodies (ANCA) was determined where possible by solid phase immuno-
assays using purified proteinase 3 (PR3) and myeloperoxidase (MPO).
After correction for multiple comparisons there were no significant
differences in the distribution of DRB1, DQB1 and DPB1 alleles between
a local control group (N = 90 for DRB1, N = 50 for DQB1 and DPB1)
and the patient group as a whole (N = 94) or two a priori defined
subgroups (anti-PR3 positive, N = 35; anti-MPO positive, N = 22). We
have therefore found no significant association between primary systemic
vasculitis and any MHC class II allele. This, together with the fact that
previous smaller studies have shown no consistent association, suggests
that any such association is very weak, if it exists at all.
Products of the major histocompatibility complex (MHC) play
a key role in the development of the immune (and autoimmune)
response. By binding antigenic peptides and presenting them to T
cells (CD8 T cells in the case of the products of the MHC class
I loci A, B and C, CD4 cells in the case of the class II loci DP,
DQ and DR) these molecules provide one of the critical signals
necessary for T cell activation [1]. Different allelic forms of the
MHC molecules differ in the repertoire of peptides that they are
able to bind [2, 3]. This variability is one of the mechanisms
underlying the association between particular MHC alleles and
the ability to mount a particular immune (or autoimmune)
response [4]. In humans, it is unusual to observe such associations
in the response to exogenous antigens, which contain many
potentially antigenic peptides and are therefore likely to be able
to form at least some productive MHC molecule-peptide com-
plexes. Autoimmunity is presumed to follow the breakdown of
tolerance to a very limited number of self peptides, and MHC-
disease associations are commonly observed [5]. Knowledge of
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such associations may identify key MHC molecules and, ulti-
mately, self peptides which might allow the development of new
therapeutic strategies; this has already been achieved in some
animal models of autoimmunity [6]. Furthermore, analysis of
MHC-disease associations may identify other linked genes with
possible therapeutic consequences [7].
The primary systemic vasculitides, Wegener's granulomatosis
(WG) and microscopic polyangiitis (MPA) [8], have long been
suspected to have an autoimmune basis. The case for this has been
strengthened by the finding of anti-neutrophil cytoplasm antibod-
ies (ANCA) in a very high proportion of cases of WG [9], MPA
[10], and renal-limited vasculitis [11]. The common clinical,
histological and serological manifestations suggest that these
three conditions are related, and belong to the same spectrum of
disease. Among other factors, discrimination within this spectrum
is possible on the basis of detailed ANCA specificity. WG is most
closely associated with ANCA that produce a cytoplasmic staining
pattern (cANCA) and that have specificity for proteinase 3 (PR3)
[9, 12], while MPA and renal-limited vasculitis are usually asso-
ciated with ANCA that exhibit a perinuclear staining pattern
(pANCA) [9], the majority having specificity for myeloperoxidase
(MPO) [11].
Autoimmune diseases are usually most closely associated with
MHC class II alleles; with some exceptions [13], class I associa-
tions are secondary, and due to linkage disequilibrium within the
MHC. We have therefore investigated the distribution of class II
alleles in a series of patients with primary systemic vasculitis and
renal-limited vasculitis. In other autoimmune diseases MHC
associations may be closer with particular autoantibody specifici-
ties than with clinical patterns of disease [14]. We therefore
defined two subgroups a priori: those with antibodies to PR3, and
those with antibodies to MPO. Molecular techniques were used
that allow typing at all three class II loci.
Methods
Patients and controls
The disease definitions used here were adapted from those
developed at a recent consensus conference on nomenclature in
systemic vasculitis [8].
Wegener's granulomatosis. Diagnosis requires clinical evidence
of a chronic inflammatory process of more than six weeks duration
affecting the respiratory tract, usually the upper airways, with or
without involvement of other organs. This should be supported
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either by histology showing a granulomatous, necrotizing vasculi-
tis of small and medium-sized vessels (such as capillaries, arte-
rioles, venules and arteries) or cANCA positivity and/or reactivity
for PR3 by ELISA.
Microscopic polyangiitis. There should be clinical evidence of a
chronic inflammatory process affecting at least two organ systems
(one is typically the kidneys) supported by histology and/or ANCA
positivity (indirect immunofluorescence or anti-PR3 or anti-MPG
autoantibodies). The histological lesion is a non-granulomatous
necrotizing vasculitis of small vessels (such as capillaries, arte-
rioles, venules and arteries), but arteritis of small and medium-
sized arteries may also occur. Renal disease is manifested by a
pauci-immune, necrotizing, crescentic glomerulonephritis.
Renal-limited vasculitis. The definition is the same as for micro-
scopic polyangiitis without evidence of extra-renal disease.
Patients presenting with one of these diagnoses listed above, or
under follow-up, were included in the study. Ninety local healthy
individuals were used as controls for DR typing, and a randomly
selected subset of 50 of these as controls for DQ and DP typing.
ANCA indirect immunofluorescence (hF)
ANCA hF was determined using a fluorescein-isothiocyanate
conjugated (FITC) mouse anti-human immunoglobulin (F200,
DAKO, Denmark; binds to IgG, IgA and 1gM) and a FITC
conjugated rabbit anti-human 1gM (F203, DAKO). Positive sera
were, when possible, classified as having a cytoplasmic (cANCA)
or pen-nuclear (pANCA) pattern [9]. In some cases the immu-
nofluorescence could not be definitely assigned to either category
and this hF was classified as indeterminate.
Anti-MPO and anti-PR3 ELISA
MPG was obtained from Calbiochem (La Jolla, CA, USA). PR3
was prepared using minor modifications of published methods.
Neutrophils were obtained by sedimentation of red cells with a
methylcellulose-hypaque gradient (2% methylcellulose, 34%
hypaque in distilled water). The supernatant was centrifuged at
250 g for 10 minutes, and remaining red cells lysed by resuspend-
ing in 0.83% NH4C1, 10 mivi KHCO3, 0.1 msi EDTA for 10
minutes. After washing with phosphate-buffered saline (PBS),
granules were isolated from the neutrophils by nitrogen cavitation
[151. Granule pellets were suspended in cold 0.1 M sodium acetate
buffer, pH 4.2, and disrupted by six freeze/thaw cycles. Following
centrifugation at 10,000 g for 20 minutes, PR3 was isolated from
the supernatant by column chromatography on Orange A and
Bio-Rex 70 [16].
For the ELISA, antigens were coated onto Dynatech microtiter
plates by incubation at 37°C for two hours (MPO 0.01 U/ml, PR3
0.2 g/ml in 0.05 M sodium bicarbonate buffer, pH 9.5). Samples
were diluted 1:50 in PBS/0.05% Tween 20/1% gelatin and incu-
bated in duplicate on the plates for one hour at 37°C. After
washing, bound antibody was detected with alkaline phosphatase-
conjugated goat anti-human IgG (1:3000, Jackson Immuno-
Research Laboratories Inc.) followed by alkaline phosphatase
substrate (Sigma). Results were calculated as the net absorbance
at 405 nm (average absorbance in antigen coated wells minus
average absorbance in antigen free wells) expressed as a percent-
age of a known positive sample included on the same plate. A
sample was designated positive if the binding was greater than
three standard deviations above the mean, derived from 30
normal control sera.
MHC class II allele lyping
The methods used in this study have been described previously
[17]. DNA was extracted from peripheral blood samples. For DR
typing, DNA was digested using Taq I and electrophoresed on an
agarose gel. The fragments were transferred to a nylon membrane
using the Southern blot method and then hybridised serially with
32P-labeled DQA1 and DRB1 probes. The results were deter-
mined by visual inspection [18]. For DQ and DP typing, the DQB1
and DPB1 regions were amplified using the polymerase chain
reaction, transferred to a nylon membrane using dot-blotting [19],
and then probed with 32P-labeled oligonucleotide probes. Restric-
tion fragment length polymorphism patterns or binding combina-
tions of oligonucleotide probes not corresponding to known
alleles were designated as untyped.
Statistics
Analysis was by chi squared test (two tailed) on 2 X 2 contin-
gency tables with Yates' correction. A correction for multiple
comparisons was made by multiplying the P values by the number
of different alleles found at each locus.
Results
A total of 94 patients were successfully typed at at least two of
the three class II loci and form the basis of this report.
Seven patients were classified as having renal-limited vasculitis.
Histological confirmation was available for all seven, and six were
pANCA positive; of the six, three were anti-MPO positive,
including one patient double positive for anti-PR3.
Thirty-one patients were classified as having microscopic poly-
angiitis. Histological confirmation was available for 26; of the
other five, four were pANCA positive (one also anti-MPO
positive), and one cANCA positive. In this group as a whole, 17
were anti-MPO positive, including one double positive for anti-
PR3, and one patient was positive for anti-PR3 alone.
Fifty-six patients were classified as having Wegener's granulo-
matosis. Histological confirmation was available for 43; of the
other 13, four were cANCA and anti-PR3 positive, six cANCA
positive alone, one cANCA, anti-PR3 and anti-MPO positive, one
pANCA and anti-PR3 positive and one cANCA and anti-MPO
positive. In this group as a whole, 32 were anti-PR3 positive,
including one double positive for anti-MPO, and one patient was
positive for anti-MPG alone.
In the patient population as a whole, histological confirmation
of the diagnosis in the form of necrotizing vasculitis and/or
crescentic glomerulonephritis was available for 76 patients (81%).
Vasculitis was generalized in 74 (79%) and renal-limited in seven
(7%). Disease was persistent in 20 of the 69 patients (29%) for
which this information was available. A total of 85 patients (90%)
were positive for ANCA by hF at some stage (55 cANCA, 29
pANCA, 1 indeterminate); the majority of the nine negative
patients had localized and/or inactive disease.
The distribution of alleles in the whole population studied is
presented in Table 1. Thirty-five patients were positive for anti-
PR3 antibodies, and 22 for anti-MPG antibodies (these numbers
include three patients that were positive for both specificities); the
distribution of alleles in these two a priori defined subgroups is
shown in Tables 2 and 3. Table 4 presents the comparisons in
which the chi squared statistic was > 1 together with the associ-
ated uncorrected P values. In no case did the chi squared statistic
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Table 1. Frequency (%) of MHC class II alleles in patients with primary small vessel vasculitis
Patients
(N = 94)
Controls
(N = 90)
Patients Controls
(N = 94) (N = 50)
Patients
(N = 94)
Controls
(N = 50)
DR1 17 19 DQ*0401/0402 1 8 DPB*01Ol 21 18
DR2 31 27 DQ*0201 35 34 DPB*0201/0801 38 30
DR3 29 37 DQ*0501 45 28 DPB*0301 22 18
DR4 44 37 DQ0602 16 24 DPB0401 75 60
DR5 16 17 DQ*0301 57 50 DPB*0402 20 24
DR6 12 19 DQ*0302 28 26 DPB*0501 5 4
DR7/9 30 21 DQ*0303 8 10 DPB*0601 3 0
DR8 10 4 Untyped 1 4 DPB*0901 5 10
Untyped 1 12
Table 2.
Untyped
Frequency (%) of MHC class II alleles in patients with anti-PR3 antibodies
1 6
Patients Controls Patients Controls Patients Controls
(N = 35) (N = 90) (N = 35) (N = 50) (N = 35) (N = 50)
DR1 17 19 DQ*0401/0402 3 8 DPB*0101 17 18
DR2 34 27 DQ*0201 37 34 DPB*0201/0801 34 30
DR3 29 37 DQ*0501 37 28 DPB*0301 11 18
DR4 57 37 DQ0602 17 24 DPB*0401 86 60
DR5 14 17 DQ*0301 69 50 DPB*0402 26 24
DR6 6 19 DQ*0302 29 26 DPB*0501 9 4
DR7/9 29 21 DQ*0303 3 10 DPB*0601 3 0
DR8 9 4 DPB*0901 9 10
Table 3. Frequency (%) of MHC class II alleles in patients with anti-MPO antibodies
Patients Controls Patients Controls Patients Controls
(N = 22) (N = 90) (N = 22) (N = 50) (N = 22) (N = 50)
DR1 18 19 DQ*0201 23 34 DPB*0101 18 18
DR2 27 27 DQ*0501 50 28 DPB*0201/0801 36 30
DR3 18 37 DQ*0602 9 24 DPB*0301 27 18
DR4 54 37 DQ0301 59 50 DPB*0401 68 60
DR5 9 17 DQ*0302 27 26 DPB*0402 23 24
DR6 14 19 DQ*0303 14 10 DPB*0501 5 4
DR7/9 36 21 Untyped 5 DPB*0601 5 0
DR8 9 4 DPB*0901 9 10
achieve significance after correction for multiple comparisons,
and indeed in only one case (DPB*0401 in patients with anti-PR3
antibodies) was this significant before correction.
Discussion
We have found no difference in the distribution of DRB1,
DQB1 or DPB1 alleles between our patient and control popula-
tions. There was a possible suggestion of an increased incidence of
DPB*0401 in patients with anti-PR3 antibodies, but because of
the multiple comparisons involved this should be interpreted with
caution. Our conclusions must be qualified somewhat because the
RFLP typing method used for the DR locus will conceal some
allelic complexity, and we may not have identified rare alleles
present as heterozygotes at the DQ and DP loci. However, given
the very similar distribution of alleles between the patient and
control populations, we regard it as unlikely that a more detailed
analysis would reveal significant differences.
A genetic component to the pathogenesis of Wegener's granu-
lomatosis is suggested by the occasional reports of occurrence of
the disease in related individuals [20—23]. However, previous
studies of the distribution of MHC alleles have produced conflict-
ing results. An initial report found no association with any of 24
class I specificities [24]. Subsequently, an association with the class
I allele B8 was found (present in 38.7% of patients vs. 18.9% of
controls; P < 0.01, but probably not corrected for multiple
comparisons [25]). A later study found a very similar increased
frequency of B8 but this was not significant after correction [26].
There was, however, a significant association between Wegener's
granulomatosis and DR2 (Pcorr < 0.008). There were no other
significant associations between Wegener's granulomatosis and
the other MHC alleles that were examined, nor between poly-
arteritis nodosa and Churg-Strauss vasculitis and any allele.
The first study to employ molecular typing techniques used
RFLP analysis to determine DR types, in addition to standard
serological typing for class I A and B locus alleles, in 41 patients
with Wegener's granulomatosis [27]. No significant associations
were found, although the greatest difference was a frequency of
43.9% for DR15 (a subtype accounting for almost all DR2 types
in the population studied) in patients compared to 30% in
controls. A study of 27 patients with Wegener's granulomatosis
using serological techniques found a significant increase in DR1
(Pcorr = 0.04) [28].
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Table 4. Alleles with chi squared statistic > 1
Group Allele Chi squared
P value
(uncorrected)
All patients DR6
DR7/9
DR8
DQB*0401/2
DQB*0501
DPB*0401
1.326
1.392
1.144
2.844
3.152
3.054
0.2496
0.238
0.2847
0.0917
0.0758
0.0805
Patients with anti-PR3
antibodies
DR4
DR6
DQB*0301
DPB*0401
3.528
2.448
2.197
5.377
0.0603
0.1177
0.1382
0.0204(P = 0.1632)
Patients with anti-MPO
antibodies
DR3
DR4
DR7/9
DQB*0501
DQB*0602
1.959
1.666
1.492
2.364
1.321
0.1616
0.1968
0.222
0.1242
0.2505
The previous largest study to date used exclusively molecular
techniques to examine the distribution of DRB1, DQA1 and
DQB1 alleles in 59 patients with ANCA-positive vasculitis [29].
This found a significant increase in the frequency of the DQw7
(DQB*0301) allele: 53% in patients versus 27.8% in controls,
'corr < 0.0025. Our study found a very similar frequency for this
allele (57%), and if we use the same control group (1103 British
Caucasoids typed by Bidwell) then we would also find that this
increased frequency is highly significant. However, the DQB*0301
allele was also found in 50% of our local control population.
Furthermore, a similar frequency has been found in a number of
independent patient groups typed using exactly the same tech-
niques as used in this study (39% in Graves' disease [17], 46% in
alopecia areata [30], 45% in Hashimoto's thyroiditis [31], 38% in
primary biliary cirrhosis [32]), although a reduced frequency of
15% was found in autoimmune Addison's disease [33]. The
DQB*0301 allele can be difficult to detect using RFLP analysis
[34], which was the method used by Bidwell. Because Spencer et
a! were aware of this problem they used a polymerase chain
reaction-allele specific oligonucleotide method to detect
DQB*0301 [29]. It may be significant that the studies using this
more accurate method report a rather similar frequency for
DQB*0301, which is higher than that found by Bidwell using
different methodology.
The only previous study to examine serologically defined sub-
groups found no suggestion of any difference between patients
with a cANCA pattern on indirect immunofluorescence and those
with a pANCA pattern [29]. Because these patterns (particularly
pANCA) encompass a number of different antigenic specificities,
their use as a grouping factor for immunogenetic analysis may
blur any associations with specific autoantibodies. Despite our use
of specific assays we were only able to detect a possible association
between DPB*0401 and anti-PR3 antibodies. Because of the
multiple comparisons and subgroups (albeit defined a priori) this
association may well have arisen by chance alone. A separate
study would be needed to determine whether or not it is a true
association. The rather low proportion of seropositive cases in our
population reflects the fact that many patients were in remission,
and that strict criteria were used to define specific binding in the
ELISA. In addition, a proportion of samples typed by hF in the
past were unavailable for analysis by specific ELISA.
The lack of an association between the MHC and primary
systemic vasculitis, despite improved definition of patient sub-
groups and use of molecular techniques for MHC typing, may
indicate significant differences in pathogenesis as compared to
diseases (such as membranous nephropathy [35] and anti-glomer-
ular basement membrane disease [36]) that do manifest such an
association. The association between infection and relapse of
vasculitis [37], the seasonal incidence and occasional preceding
viral illness [38], and the response in some cases to anti-microbial
therapy alone [39] all draw attention to the role of infection. If
vasculitis is precipitated by an abnormal or exaggerated response
to infection [9] then, for the reasons outlined above, it would be
unusual to observe any particular MHC association with this
response.
In conclusion, we have found no significant association between
primary systemic vasculitis and any MHC class II allele. This,
together with the fact that previous smaller studies have shown no
consistent association, suggests that any such association is very
weak, if it exists at all. This may or may not have implications for
the underlying pathogenesis, but suggests that therapeutic strate-
gies targeted at a particular MHC molecule or self-peptide are
unlikely to be applicable to this group of diseases.
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